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BENZODIAZEPINES (BDZs) are known to act not only in
the central nervous system, but  on peripheral cells
and tissues binding to the peripheral-type benzodia-
zepine receptors. In the present study, the influence
of two different BDZs (diazepam (Dz) and tofizopam
(Tof)) on several immune functions has been exam-
ined in vitro. Some differences between Dz and Tof in
their  effects  on  human  lymphocyte  proliferative
response,  changes  in  glucocorticoid-induced  sup-
pression of cell proliferation and influence on cyto-
kine production (tumor necrosis factor-a (TNF-a ) and
interleukin-2  (IL-2))  have  been  determined.  Dz sup-
pressed  mitogen-induced  peripheral  blood  mono-
nuclear  cell  (PBMC)  proliferation,  enhanced  dex-
amethasone-induced inhibition of PBMC proliferative
response, and suppressed lymphocyte production of
TNF-a and IL-2. Tof usually enhanced PBMC prolifera-
tion and IL-2 production in low and moderate doses,
but  in  high  doses  it  suppressed  both.  Tof  in  all
investigated doses enhanced dexamethasone-induced
suppression  of  lymphocyte  proliferation  and
depressed TNF-a production. Thus, both Dz and Tof
are  shown  to  have  immunomodulating  effects  in
vitro. Tof,  opposite  to  Dz  even  in  the  therapeutic
doses,  is  able  to  enhance  in  vitro mitogen-induced
lymphocyte proliferation and IL-2 production. 
Key  words:  Benzodiazepines,  Tofizopam,  Diazepam,
Immunomodulating effects, Human peripheral blood mono-
nuclear cells, Dexamethasone susceptibility, TNF-a, IL-2
Introduction
During the past two decades, it has become clear that
the immune  system responds to a great amount of
factors  originating  in  the  endocrine,  central  and
autonomic nervous systems. Recently, it has become
clear  that  there  is  also  a  feedback  loop  from  the
immune  system to the other systems. (The reverse
direction of influence also exists.) The regulation of
neuroendocrine  function  is  highly  sensitive  to  the
wide  array  of  cytokines  released  from  activated
immune  cells.1,2 The  bi-directional  communication
between these systems is based on the expression of
mediators, receptors and use of signal transduction
mechanisms that are common to both immune and
endocrine cells and to neurons and glia in the central
nervous system (CNS).2,3
One  of  the  important  links  in  the  neuro-immu-
noendocrine relations are the central and peripheral
benzodiazepine  receptors  (BDZ-R),  which  together
with their ligands form the molecular basis of a novel
regulatory network that contributes to the effects of
anxiety on immune status.4 Benzodiazepines (BDZs)
are frequently prescribed because of their anxiolytic,
anticonvulsant, muscle-relaxant and hypnotic proper-
ties. Many articles reviewed the important topic of
the complex relations between BDZs, the stress axes
(hypothalamo-pituitary-adrenal  and  autonomic)  and
the immune system.4–6
Two  types  of  BDZ-R  have  been  identified.  The
first,  namely  central  BDZ  receptors (CBR),  present
exclusively in the CNS and are localized to neurons.7
BDZs bind to a domain that regulates chloride flux
by modulating  a-aminobutyric acid (GABA)  binding
to GABAA receptors.8The second class is the periph-
eral-type BDZ receptors (PBR) that are ubiquitously
distributed in peripheral tissues9 as well as in glia of
the CNS.10 Our understanding of the PBR is still far
from complete. They participate in cholesterol trans-
port,  heme  biosynthesis,  proliferation  of  different
cell  lines  and  immunomodulation.5 It  has  been
suggested now that the PBR may serve as a receptor
in  immune  cells,  which  can  be  a  critical  locus  in
the  inter-relation  between  brain,  behavior  and
immunity.11
The BDZs diazepam (Dz)9 and tofizopam (Tof)12,13
are related to a mixed type of BDZs that interact both
with CBR and PBR by different mechanisms.12,13 In
man, Tof (a 2,3-benzodiazepine) has been shown to
have anxiolytic activity but, in contrast to the widely
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sedative and muscle relaxant effects.12,14
In the present study, some differences between Dz
and Tof in their effects on several immune functions
in vitro are described.
Material and methods
Cell cultures
Peripheral  blood  mononuclear  cells  (PBMC)  were
isolated from heparinized peripheral blood of healthy
volunteers by Ficoll-Verographin gradient centrifuga-
tion. The cells were washed twice and resuspended in
RPMI-1640  medium  (ICN,  Irvin,  CA,  USA)  supple-
mented with 2 ´ 10–3M HEPES, 2 mM  L-glutamine,
2.8 ´ 10–6M 2-mercaptoethanol, 20mg/ml of genta-
mycin  and  different  serums.  Ten  percent  of  heat-
inactivated fetal calf serum (FCS) (ICN) were used for
PBMC proliferation, tumor necrosis factor-a (TNF-a)
production and interleukin-2 (IL-2) assay, and 1% of
FCS used for IL-2 production.
Lymphocyte proliferation
PBMC were cultivated in flat-bottomed 96-well plates
(Nunc,  Roskild,  Denmark),  and  contained  5 ´ 104
cells in each well. The final concentration of phyto-
hemagglutinin  (PHA)  (Calbiochem,  La  Jolla,  CA,
USA)  was  5mg/ml.  Modulation  of  lymphocyte  pro-
liferation by Tof and Dz was evaluated at four different
concentrations  within  the  dose  ranges  of
0.4–50mg/ml for Tof and of 0.04–5mg/ml for Dz. The
control  wells  incubated  without  BDZs  contained  a
culture medium with mitogen or a culture medium
only. The influence of Tof and Dz on the inhibition of
PHA stimulation by dexamethasone (Dx) (Sigma, St.
Louis, MO, USA) was also evaluated. Dx was used at
the  concentrations  of  10–8 and  10–7M  with  or
without (control wells) the above doses of Tof and Dz.
The  cells  were  incubated  for  72h  at  37°C  in  a
humidified atmosphere (95% air, 5% CO2). Four hours
before the end of cultivation, each well was pulsed
with  40kBq  of  [3H]-thymidine  (Isotope,  Moscow,
Russia). The cells were harvested with a cell harvester
and  counted on  a liquid  scintillation  counter.  Four
wells  of  each  concentration were  assayed  and  the
counts per minute (count/min) were averaged.
TNF-a production
Cells (106 cells/ml) were cultivated for 16h at 37°C
with  5mg/ml  of  PHA  and  BDZs  at  three  different
concentrations  (7.5,  15  and  30mg/ml  for Tof,  and
1.25,  2.5  and  5mg/ml  for  Dz)  in  a  humidified
atmosphere containing 5% CO2 in the wells (1.5ml
per well) of 24-well  plates (Nunc). The cells in the
control  wells  were  incubated  with  PHA  only. The
supernatants were collected and stored at –20°C until
cytokine activity examination.
IL-2 production
PBMC  in  the  concentration  of  106 cells/ml  were
resuspended in the culture medium with 20mg/ml of
concanavalin A  (Calbiochem). The  cells  were  incu-
bated (see earlier) for 16h in the wells (1.5ml per
well)  of 24-well  plates (Nunc) with the addition of
BDZs at three different concentrations (7.5, 15 and
30mg/ml for Tof, and 1.25, 2.5 and 5mg/ml for Dz).
The cells in the control wells were incubated with
concanavalin A only. The supernatants were collected
and stored at –20°C until use.
TNF activity assay
TNF activity was determined by the method of Ruff
and Gifford15 with some modifications. Briefly, L929
cells were seeded at a density of 3 ´ 104 cells per well
in 96-well plates in 100ml of medium 199 to which
10% heat-inactivated calf bovine serum and gentamy-
cin had been added. Plates were incubated at 37°C in
a humidified atmosphere containing 5% CO2 until the
monolayer formation. After the culture medium elim-
ination, twofold serial dilution of the samples (100ml
of each dilution) and 100ml of fresh culture medium
with 20mg/ml of actinomycin D (Serva, Heidelberg,
Germany) were added, and further incubated for 18h
under the same conditions. Supernatants were then
removed  and  cells  stained  with  0.2%  crystal  violet
(Sigma). After washing and drying, plates were finally
read  at  594nm  on  a Titertek  Multiskan  microElisa
reader. Human recombinant TNF-a (Institute of Bio-
organic  Chemistry,  Moscow,  Russia)  was  used  as
internal  standard.  For  the  comparison  of  experi-
mental  and  calibrating  curves,  a  probit-analysis
method was used.16The TNF content in the samples
was expressed in picograms per milliliter.
IL-2 activity assay
The amount of  IL-2 in  separate samples was deter-
mined by their ability to maintain the growth of the
IL-2-dependent cytotoxic T-cell line (CTLL-2). Super-
natants were  twofold  serially  diluted and 100ml  of
samples from each dilution and 100ml of CTLL cell
suspension (4 ´ 103 cells  per well)  were added to
triplicate  wells  of  a  96-well  flat-bottomed  plate.
Triplicate cell control wells received 100ml of culture
medium instead of samples. Recombinant human IL-2
(code  No  86/564;  National  Institute  for  Biological
Standards and  Control, Hertfordshire, UK)  and  IL-2
containing  preparation  Ronkoleukin  (Cytokine,  St.
Petersburg, Russia) were used as standards. After 20h
incubation at 37°C and 5% CO2, the colorimetric MTT
assay  was  carried  out17 with  some  modifications.
S.V. Kalashnikov et al.
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.Briefly, 20ml of 5mg/ml MTT (Sigma) stock solution
were added to each well. Plates were incubated again
at the same conditions for 4h. The supernatants were
then  removed  and  100ml  of  dimethylsulfoxide
(Sigma)  were  added  to  all  wells  to  dissolve  the
crystals. The plates were read at 570nm on a Titertek
Multiskan microElisa  reader. The  titration curves  of
the tested samples and the controls were analyzed by
probit analysis.16The content of IL-2 was expressed in
international units per milliliter.
Statistical analysis
Statistical analysis was performed using the Student’s
t-test  with  Bonferroni  correction  for  multiple
comparisons.
Results
PBMC proliferation in the presence of Dz and
Tof
Dz  in  a  high  dose  (1–5mg/ml),  to  a  considerable
extent, suppressed cell proliferation (Fig. 1) and, as a
rule, had no effect in a low dose (0.04–0.2mg/ml).
The  enhancing  effect of  Dz  on  PBMC  proliferation
was observed only with lymphocytes of donor N. But
in  this  very  case,  the  higher  doses  of  Dz  and Tof
caused the greater increase in PHA-induced lympho-
cyte proliferation.
Tof  usually  enhanced  cell  proliferation  (Fig.  1,
donors H, K, P and N). Only  in  high doses (10  or
50mg/ml)  and  only  in  three  cases  from  seven
(donors  C,  D  and  S)  did Tof  significantly  suppress
PBMC blast transformation. It should be noted that
in  three cases the  curves  of  the  both  BDZs  had  a
nearly  complete  coincidence (donors  N,  C  and  S),
but  the  profile  of  the  other  curves  was  different
(donors  H,  K,  P  and  D). Thus, Tof  could  reliably
enhance  PBMC  proliferation  in  low  and  moderate
doses, whereas Dz caused significant suppression in
doses of 1 and 5mg/ml (or only 5mg/ml) and had no
effect in lower doses.
Changes in Dx-mediated inhibition of
PHA-induced lymphocyte proliferation
Changes  in  lymphocyte  susceptibility  to  glucocor-
ticoid hormones caused by Tof and Dz are presented
in Table 1. Dose-dependent enhancing of Dx-mediated
inhibition  of  PHA-induced lymphocyte  proliferation
was observed as for Tof and for Dz at two corticoste-
roid concentrations (10 and 100nM). It is necessary
to mention that, with donors H, K and P, lymphocytes
tofizopam itself caused the rise of lymphocyte pro-
liferation  (Fig.  1)  but,  in  the  presence  of  Dx, Tof
increased its suppression. Significant suppression of
lymphocyte  proliferation  in  comparison  with  pro-
liferative response only with Dx without BDZs was
shown  for  high  and  average  doses  of Tof  and  Dz.
S.V. Kalashnikov et al.
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Table 1. Changes in dexamethasone (Dx)-mediated inhibition of phytohemagglutinin (PHA)-induced lymphocyte proliferation
caused by different doses of tofizopam (Tof) and diazepam (Dz)
Dx dose (nM) Tof/Dz Dose (mg/ml) Donor K Donor P Donor C Donor H Donor D
10 Tofizopam – 123 ± 3.4 56 ± 9.1 49 ± 6.6 34 ± 2.5 24 ± 1.3
0.4 103 ± 7.9 48 ± 11.9 49 ± 5.6 30 ± 1.2 23 ± 1.9
2 85 ± 3.7* 54 ± 5.5 37 ± 0.7 30 ± 1.4 22 ± 1.1
10 85 ± 8.3* 42 ± 6.7 35 ± 4.6 29 ± 1.7 21 ± 0.5
50 74 ± 4.9* 42 ± 2.9 31 ± 2.5 25 ± 1.7 13 ± 1.7*
100 Tofizopam – 31 ± 2.2 32 ± 4.7 5.4 ± 0.7 17 ± 1.7 11 ± 0.4
0.4 23 ± 2.3 27 ± 4.3 5.3 ± 1.3 15 ± 1.9 11 ± 1.6
2 26 ± 4.8 22 ± 4.3 3.9 ± 0.8 7.2 ± 0.9* 8.4 ± 1.2
10 23 ± 1.3* 21 ± 2.5 4.1 ± 0.1 7.9 ± 0.5* 8.7 ± 0.4*
50 15 ± 2.6* 15 ± 4.4* 2.9 ± 0.3* 6.6 ± 0.8* 7.3 ± 1.6
10 Diazepam – 123 ± 7.7 56 ± 9.1 49 ± 6.6 34 ± 2.5 24 ± 1.3
0.04 121 ± 3.6 90 ± 5.7* 40 ± 9.2 38 ± 2.7 30 ± 2.2
0.2 91 ± 1.8* 70 ± 8.9 35 ± 3.7 30 ± 2.7 28 ± 1.9
1 74 ± 4.1* 48 ± 3.0 26 ± 0.7* 25 ± 2.2 18 ± 1.1*
5 24 ± 3.3* 29 ± 6.0* 17 ± 2.9* 11 ± 0.4* 4.6 ± 0.6*
100 Diazepam – 31 ± 2.2 32 ± 4.7 5.4 ± 0.7 17 ± 1.7 11 ± 0.4
0.04 31 ± 8.6 29 ± 5.5 5.2 ± 0.9 18 ± 4.1 11 ± 1.3
0.2 21 ± 2.6* 26 ± 2.6 4.6 ± 0.7 8.4 ± 0.8* 11 ± 0.2
1 15 ± 1.2* 21 ± 3.3 3.6 ± 0.8 8.1 ± 1.9* 6.0 ± 0.7*
5 4.8 ± 1.1* 5.7 ± 1.1* 2.2 ± 0.9* 2.5 ± 0.6* 2.4 ± 3.3*
PHA-stimulated donor’s peripheral blood mononuclear cells (PBMC) were cultivated (see ‘Materials and methods’) with 10 or 100nM of Dx and
with or without different doses of Tof and Dz.
Data are presented as counts permin ´ 1000 and are expressed as mean ± standard error of the mean. Donors K, P, C, H, and D correspond to
healthy volunteers.
*p < 0.05; in comparison with mean proliferative response only with Dx, without BDZs (–); Student’s t-test with Bonferroni correction for multiple
comparisons. Proliferation of the same donor’s PBMC without Dx can be seen in Fig. 1.Enhancing  of  Dx-induced  suppression  by  BDZs
did  not  depend  on  individual  susceptibility  to
glucocorticoids.
Changes in TNF production
In the experiments of cytokine production, we used
not so wide but therapeutically used range of doses of
BDZs. We examined the influence of  Tof and Dz on  TNF-
a production by PHA-stimulated PBMC of five healthy
volunteers.  Neither Tof  nor  Dz  in  analyzed  doses
affected the growth of the L929 test-cell line. Dose-
dependent suppression of TNF-a production has been
shown for both of the BDZs (Fig. 2) (p < 0.05).
Changes in IL-2 production
The influence of Tof (7.5, 15 and 30mg/ml) and Dz
(1.25,  2.5  and  5mg/ml)  on  IL-2  production  was
examined  on  lymphocytes  of  three  healthy  volun-
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FIG. 2. The effect of tofizopam and diazepam on in vitro TNF-a production by PBMC of five healthy donors. The supernatants
were obtained and collected, and the TNF-a activity was quantified as described in ‘Materials and methods’. D, A, K, Z, C,
initials of the healthy volunteers. * p < 0.05 compared with the control value of each donor (Student’s t-test with Bonferroni
correction for multiple comparisons).
FIG. 3. The effect of tofizopam and diazepam on in vitro IL-2 production by PBMC of three healthy donors. The supernatants
were obtained and collected, and the IL-2 activity was quantified as described in ‘Materials and methods’. D, A, K, initials of
healthy volunteers. * p < 0.05 compared with the control value of each donor (Student’s t-test with Bonferroni correction for
multiple comparisons).teers. The  enhancing  effect  on  IL-2  release  treated
with Tof  was  marked  with  PBMC  from  all  of  the
volunteers  (Fig.  3).  Not  all  of  the  doses  gave  an
expressed  effect.  The  doses  of  7.5  and  15mg/ml
significantly  stimulated  production  of  this  cytokine
for two donors (Fig. 3, donors A and K; p < 0.05). The
dose of  7.5mg/ml  insignificantly  enhanced and  the
dose 15 of mg/ml significantly suppressed IL-2 release
from lymphocytes of donor D. The dose of 30mg/ml
(maximal  therapeutic  concentration  in  serum)  sig-
nificantly suppressed IL-2 production for all donors (p
< 0.05). Our results indicate that the effect of Tof on
IL-2  production  could  vary  from  marked  enhance-
ment to appreciable suppression. Thus, we notice a
dose-dependent  bell-shaped  curve.  Also,  the  same
dose could elicit different effects for different individ-
uals. Dz as opposed to Tof suppressed IL-2 production
in all investigated doses (p < 0.05), but also in this
case  the  identical  doses  cause  various  degrees  of
effects for different individuals.
It  should  be  mentioned that only  high  doses  (>
50mg/ml  for Tof  and  >  10mg/ml  for  Dz)  of  BDZs,
which  were  not  used  in  the  experiments,  slightly
reduced CTLL proliferation.
Discussion
The  presented  results  indicate  that  the  mixed-type
BDZs diazepam and tofizopam are able to modulate
the immune responses in vitro: lymphocyte prolifera-
tion response management, change in glucocorticoid
susceptibility and influence on cytokine production
(TNF-a, IL-2). The former behaves as an immunosup-
pressive agent in therapeutic doses, whereas the latter
seems to upregulate immune functions (PBMC blast
transformation, IL-2 production) in some conditions.
This modulation in vitro is  realized  not  through
CBR but through PBR, at least partially. PBR have been
identified  on  thymocytes,18 macrophages,19 neutro-
phils,20 leukocytes21 and lymphocytes.22 The PBR is
implicated in both stimulation of cell growth rate and
DNA  synthesis  and  in  inhibition  of  cell  prolifera-
tion.23,24 The former requires nanomolar concentra-
tions, whereas the latter requires micromolar concen-
trations of PBR ligands. This ambiguity of the PBR in
the mediation of benzodiazepine-induced effects on
mitosis has been suggested to be due to the existence
of  receptor subtypes25 or another BDZ  low affinity
binding  site  (platelet-activating  factor  receptor26).
The  immunomodulatory  action  of  benzodiazepines
may  be  of  pharmacological  importance  because,
during their application, their plasma concentrations
reach micromolar levels.
It is known that chronically treated BDZ users had
some  alterations  in  immune  and  neuroendocrine
system.27Hence it is necessary to emphasize meaning
of the received data about an opportunity of BDZs to
increase  corticosteroid-induced  (stress-induced)
immunosuppression. It is more interesting to search
among the novel BDZs,28 those with immunostimula-
tory  activity.  Tof  as  opposed  to  Dz,  even  in  the
therapeutic  doses,  is  able  to  enhance  in  vitro
mitogen-induced  lymphocyte  proliferation  and  IL-2
production.
Each  person  has  an  individual  susceptibility  to
mitogen or antigen-induced lymphocyte stimulation,
glucocorticoids and BDZs. That is why a certain type
of BDZ should be administered in individually selec-
ted  doses  and  courses. They  should  be  prescribed
with  caution,  especially  to  immunocompromised
patients  (e.g.  because  of  aging,  treatment  with
immunosuppressive  drugs,  suffered  from  chronic
obstructive pulmonary disease (COPD), chronic heart
or renal failures, etc.).
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